Intra-Cellular Therapies (ITCI) stock price, revenue, and financials

Intra-Cellular Therapies market cap is $2.2 b, and annual revenue was $60.61 k in FY 2019

$2.2 B

ITCI Mkt cap, 23-Sept-2020

$1.9 M

Intra-Cellular Therapies Revenue Q2, 2020
Intra-Cellular Therapies Net income (Q2, 2020)-63.7 M
Intra-Cellular Therapies EBIT (Q2, 2020)-64.9 M
Intra-Cellular Therapies Cash, 30-Jun-2020129.3 M
Intra-Cellular Therapies EV2.1 B

Intra-Cellular Therapies Revenue Breakdown

Embed Graph

Intra-Cellular Therapies revenue breakdown by business segment: 33.6% from License and collaboration revenue and 66.4% from Grant Revenue

Intra-Cellular Therapies Income Statement

Intra-Cellular Therapies Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

35.2m61.3m47.2m48.6m37.8m54.9m107.6m

Accounts Receivable

336.3k51.6k30.7k94.3k

Prepaid Expenses

762.2k1.3m8.0m4.9m7.9m6.3m

Inventories

4.0m

Current Assets

38.2m131.0m483.3m388.2m469.2m355.4m230.3m

PP&E

68.3k54.6k775.5k627.6k1.1m1.2m2.3m

Total Assets

38.4m131.1m484.1m388.9m471.5m357.2m251.2m

Accounts Payable

3.4m2.1m1.6m3.8m6.2m14.0m7.4m

Short-term debt

Current Liabilities

6.8m10.6m6.3m10.5m14.2m36.3m36.2m

Long-term debt

20.0m

Total Debt

20.0m

Total Liabilities

7.9m13.4m17.0m39.5m56.2m

Common Stock

2.2k3.0k4.3k5.5k5.5k5.6k

Additional Paid-in Capital

89.2m208.9m669.9m685.3m862.5m880.8m905.0m

Retained Earnings

(57.6m)(88.3m)(193.0m)(309.5m)(407.2m)(562.4m)(710.1m)

Total Equity

31.6m120.6m476.2m375.5m454.4m317.7m195.0m

Financial Leverage

1.2 x1.1 x1 x1 x1 x1.1 x1.3 x

Quarterly

USDQ1, 2014Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

49.044.1m143.6m91.1m68.9m100.8m71.4m332.8m37.2m52.0m200.4m23.6m29.6m52.3m74.4m69.8m69.8m64.1m91.8m102.2m179.6m129.3m

Accounts Receivable

251.3k167.8k219.2k124.4k3.3k9.1k98.2k1.3k68.2k61.9k6.3k1.4m2.4m

Prepaid Expenses

806.3k585.1k493.4k1.4m1.3m8.6m1.5m6.8m4.0m4.0m3.8m6.1m5.3m6.1m5.9m7.3m8.3m3.0m4.0m7.9m4.7m

Inventories

1.4m2.3m

Current Assets

49.047.1m146.4m141.2m137.5m236.5m212.6m512.3m462.9m446.8m541.8m371.6m348.8m333.4m443.2m409.7m383.3m321.1m288.3m259.5m461.0m418.6m

PP&E

75.7k65.1k63.9k57.4k559.7k722.1k785.5k731.4k718.7k677.7k605.7k628.9k679.6k1.3m1.3m1.2m1.1m2.1m2.2m2.1m2.0m

Total Assets

49.047.3m146.6m141.3m137.6m237.1m213.4m513.1m463.7m447.6m542.6m372.3m349.5m334.2m445.6m412.1m385.6m343.0m309.9m280.5m481.2m440.9m

Accounts Payable

23.7k4.0m2.1m415.8k503.9k4.6m4.9m705.0k2.0m3.9m5.4m7.2m1.8m4.4m10.0m5.4m10.5m8.6m5.6m6.2m11.0m5.5m

Short-term debt

3.2m4.0m

Current Liabilities

33.0k7.8m3.9m2.7m3.6m14.6m9.3m10.4m8.9m19.4m140.7m16.3m7.0m11.9m19.7m18.9m29.1m33.5m32.5m33.4m31.1m40.2m

Long-term debt

20.9m20.6m20.3m19.7m21.2m

Non-Current Liabilities

160.1k2.0m2.3m2.6m2.9m2.9m2.9m

Total Debt

20.9m20.6m20.3m22.9m25.1m

Total Liabilities

14.8m9.8m11.3m10.9m21.6m143.3m19.3m9.9m14.8m22.5m21.7m32.0m54.4m53.1m53.6m50.8m61.4m

Common Stock

500.02.2k2.9k2.9k2.9k3.5k3.5k4.3k4.3k4.3k4.3k4.3k4.3k4.3k5.5k5.5k5.5k5.5k5.5k5.5k6.6k6.7k

Additional Paid-in Capital

9.5k89.1m204.8m205.3m207.2m332.9m335.7m666.1m673.7m677.6m681.5m689.7m694.1m696.7m867.2m871.5m876.1m885.9m891.2m896.2m1.2b1.2b

Retained Earnings

(49.5m)(62.1m)(66.6m)(73.1m)(110.5m)(132.1m)(164.2m)(220.9m)(251.7m)(282.0m)(336.4m)(354.2m)(377.0m)(442.7m)(480.1m)(521.6m)(597.2m)(634.7m)(669.5m)(757.5m)(821.2m)

Total Equity

(33.0k)39.6m142.7m138.6m134.0m222.4m203.6m501.9m452.7m426.0m399.3m353.0m339.7m319.4m423.2m390.4m353.6m288.6m256.8m226.9m430.4m379.5m

Financial Leverage

0 x1.2 x1 x1 x1 x1.1 x1 x1 x1 x1.1 x1.4 x1.1 x1 x1 x1.1 x1.1 x1.1 x1.2 x1.2 x1.2 x1.1 x1.2 x

Intra-Cellular Therapies Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(26.9m)(30.7m)(104.8m)(116.4m)(97.8m)(155.1m)(147.7m)

Depreciation and Amortization

23.2k25.5k139.6k196.9k213.9k368.7k477.1k

Accounts Receivable

(35.9k)284.7k20.9k(63.7k)94.3k

Accounts Payable

3.4m(1.3m)(419.9k)2.1m2.4m7.8m(6.5m)

Cash From Operating Activities

(22.6m)(22.8m)(102.3m)(91.3m)(80.5m)(118.2m)(128.0m)

Purchases of PP&E

(33.3k)(11.8k)(860.6k)(49.0k)(723.4k)(391.3k)(700.4k)

Cash From Investing Activities

1.5m(66.7m)(361.8m)92.3m(92.7m)134.6m177.4m

Short-term Borrowings

(125.0m)

Cash From Financing Activities

40.6m115.7m449.9m477.7k162.4m685.2k3.2m

Net Change in Cash

19.5m26.2m(14.2m)1.5m(10.9m)17.2m52.7m

Interest Paid

11.3k7.1k36.8k

Income Taxes Paid

31.4k45.0k1.0m1.6k1.6k

Quarterly

USDQ1, 2014Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(10.9k)(18.8m)(4.5m)(9.1m)(15.5m)(22.3m)(43.8m)(76.0m)(27.8m)(58.7m)(88.9m)(26.9m)(44.7m)(67.6m)(35.5m)(72.9m)(114.4m)(34.8m)(72.3m)(107.1m)(47.4m)(111.1m)

Depreciation and Amortization

15.8k6.3k12.7k19.2k15.2k47.1k92.6k48.0k96.7k146.8k50.4k101.8k155.3k82.5k178.3k273.2k101.4k206.4k335.5k148.8k281.1k

Accounts Receivable

49.1k168.5k117.1k211.9k48.3k42.5k51.6k30.7k(67.6k)29.4k26.1k32.4k88.0k(1.4m)(2.4m)

Inventories

(1.4m)(2.3m)

Accounts Payable

2.4k4.0m(1.3m)(3.0m)(2.9m)2.5m2.9m(1.3m)326.4k2.3m3.8m3.4m(2.0m)653.0k3.9m(794.7k)4.3m(5.4m)(8.3m)(7.7m)3.6m(2.0m)

Cash From Operating Activities

(9.9k)(14.0m)(7.0m)(12.2m)(16.6m)(15.7m)(46.7m)(67.2m)(19.7m)(33.1m)(62.8m)(16.4m)(41.3m)(55.7m)(27.0m)(60.6m)(89.0m)(35.6m)(62.9m)(92.9m)(51.2m)(98.3m)

Purchases of PP&E

(33.3k)(3.1k)(8.3k)(8.3k)(520.4k)(714.7k)(823.6k)(3.9k)(39.9k)(49.0k)(28.5k)(103.1k)(207.3k)(295.1k)(316.5k)(332.5k)(67.2k)(1.1m)(1.4m)(22.0k)(22.0k)

Cash From Investing Activities

1.5m(3.1k)(47.5m)(65.3m)(66.7m)(65.3m)(110.8m)9.6m37.6m90.6m(8.9m)22.0m59.2m63.3m92.2m120.5m44.7m99.5m139.7m(153.0m)(160.7m)

Cash From Financing Activities

5.9k40.9m115.5m115.6m115.7m121.9m122.1m449.6m163.7k348.0k125.5m224.2k230.8k230.8k337.8k343.9k499.3k31.2k290.4k442.8k277.6m282.0m

Net Change in Cash

(4.0k)28.4m108.5m56.0m33.8m39.5m10.1m271.5m(9.9m)4.8m153.2m(25.0m)(19.1m)3.7m36.6m32.0m32.0m9.1m36.8m47.2m73.4m23.1m

Interest Paid

5.0k7.1k7.1k

Income Taxes Paid

3.9k27.9k40.6k1.6k206.6k

Intra-Cellular Therapies Ratios

USDQ1, 2014

Intra-Cellular Therapies Operating Metrics

FY, 2017

Patents and Patent Applications

80